跳至主要内容
临床试验/CTRI/2020/02/023296
CTRI/2020/02/023296招募中未知

Effect of Oral Ketamine as Analgesic Adjuvant to Oral Morphine, Amitriptyline and Pregabalin on cancer pain relief, opioid analgesic consumption and functional improvement in patients with cancer: Prospective, Double Blind, Randomized Controlled Trial

HCG Cancer Centre0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
招募中
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • Age 18 to 75 years
  • Patients with malignant solid tumors
  • Patients with cancer pain of Numerical Rating Scale greater than or equal to 4, not controlled by Oral Morphine 60 mg per day and, neuropathic pain medications Oral Amitriptyline 50 mg per day and Oral Pregabalin 150 mg per day

排除标准

  • Patients who had received Ketamine for chronic pain within 6 months
  • Comorbidities contraindicating the use of Ketamine(e.g. history of hypertension or on antihypertensive therapy, history of heart failure, history of angina & myocardial infarction in last 6 weeks, aneurysm, cerebral trauma)
  • Patient with history of substance use disorder
  • Patients not able to take oral drugs
  • Patients with coexisting liver or renal disease
  • Patients who received radiotherapy or surgical therapy within past 2 months
  • Patients having pain as a side effect of chemotherapy
  • Patients with brain metastases of cancer

研究者

发起方
HCG Cancer Centre

相似试验